S. Yati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Yati has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Htet Lin Aung
European Academy of Neurology, Vienna, Austria
3 shared publications - Kaung Wai Yan Lwin
University of Medicine 2, Yangon, Myanmar
1 shared publication - Zaw Zaw Htun
Department of Medical Research, Ministry of Health and Sports, Myanmar
1 shared publication
Latest Publications
- Open Access
- 23 February 2026
- Published by Cifra Ltd – Russian Agency for Digital Standardization (RADS) publishing
Neurobiological Mechanisms and Management of Long-COVID Insomnia: A Global Systematic Review and Meta-Analysis
Background: Many people experience insomnia as a debilitating symptom of Long-COVID even though this is one of the more prevalent clinical syndromes. Nearly 50% of Long-COVID survivors have insomnia, creating a major obstacle for functional recovery due to the lack of clear neurobiological explanations for insomnia's clinical features, and fragmented evidence for specific interventions. As a result, this meta-analysis determined the prevalence of Long-COVID Insomnia, along with the multi-systemic pathophysiologic mechanisms responsible for Long-COVID Insomnia and determined the most effective therapeutic approaches available through research evidence. Methods: Following PRISMA 2020 guidelines, we conducted a search across PubMed, Scopus, and Web of Science (2020-2025). We synthesized 53 high-quality studies (1,245 initial records) using random effects meta-analysis in R Studio. We assessed pooled prevalence, neurobiological correlates (IL-6, autonomic markers) and SMDs for intervention effects. Results: The finding indicates a significantly larger pool for insomnia is 41.5% (95% CI: between 37 and 45%). Most frequently, individuals who are female or older are at the greatest risk; therefore, we can conclude that age (OR=2.30) and sex (OR=1.76) predict risk. Based on mapping a pathophysiological signature of insomnia, 58% of individuals exhibited a neuroimmune signature of elevated IL-6, coupled with significant autonomic stability issues (r = 0.34). The strongest evidence supporting effective treatments for insomnia is derived from Cognitive Behavioral Therapy for Insomnia (CBT-I) and most of the pharmacological interventions are inferior (melatonin SMD = -0.8). Conclusion: The insomnia associated with Long-COVID represents a major public health concern caused by a complicated interaction between autonomic dysfunction and neuroinflammation. This study established cognitive-behavioral therapy and melatonin as the preferred first-line treatments for restoring sleep quality in individuals with post-viral illness; therefore, inclusion of both therapies into standard Long-COVID care is crucial to prevent long-term cognitive impairment and improve functional status.
- 23 February 2026
- Published by Cifra Ltd – Russian Agency for Digital Standardization (RADS) publishing
Open AccessNeurobiological Mechanisms and Management of Long-COVID Insomnia: A Global Systematic Review and Meta-Analysis
Background: Many people experience insomnia as a debilitating symptom of Long-COVID even though this is one of the more prevalent clinical syndromes. Nearly 50% of Long-COVID survivors have insomnia, creating a major obstacle for functional recovery due to the lack of clear neurobiological explanations for insomnia's clinical features, and fragmented evidence for specific interventions. As a result, this meta-analysis determined the prevalence of Long-COVID Insomnia, along with the multi-systemic pathophysiologic mechanisms responsible for Long-COVID Insomnia and determined the most effective therapeutic approaches available through research evidence. Methods: Following PRISMA 2020 guidelines, we conducted a search across PubMed, Scopus, and Web of Science (2020-2025). We synthesized 53 high-quality studies (1,245 initial records) using random effects meta-analysis in R Studio. We assessed pooled prevalence, neurobiological correlates (IL-6, autonomic markers) and SMDs for intervention effects. Results: The finding indicates a significantly larger pool for insomnia is 41.5% (95% CI: between 37 and 45%). Most frequently, individuals who are female or older are at the greatest risk; therefore, we can conclude that age (OR=2.30) and sex (OR=1.76) predict risk. Based on mapping a pathophysiological signature of insomnia, 58% of individuals exhibited a neuroimmune signature of elevated IL-6, coupled with significant autonomic stability issues (r = 0.34). The strongest evidence supporting effective treatments for insomnia is derived from Cognitive Behavioral Therapy for Insomnia (CBT-I) and most of the pharmacological interventions are inferior (melatonin SMD = -0.8). Conclusion: The insomnia associated with Long-COVID represents a major public health concern caused by a complicated interaction between autonomic dysfunction and neuroinflammation. This study established cognitive-behavioral therapy and melatonin as the preferred first-line treatments for restoring sleep quality in individuals with post-viral illness; therefore, inclusion of both therapies into standard Long-COVID care is crucial to prevent long-term cognitive impairment and improve functional status.
- Open Access
- 15 December 2025
- Published by Cifra Ltd – Russian Agency for Digital Standardization (RADS) publishing
- Vol. 1 (1) , 5-15
Meditation as a Tool for Symptom Relief in Schizophrenia: Bridging Neuroscience and Mental Health
Background: Schizophrenia, characterized by symptoms such as auditory and visual hallucinations, imposes significant challenges on mental health care. Recent research highlights the potential of meditation to alleviate symptoms by enhancing emotional regulation and neuroplasticity. This study examines the role of meditation as an adjunctive therapy for schizophrenia, exploring its neurobiological underpinnings and practical integration into care models. Methods: A mixed-methods approach was employed. Quantitative data were analyzed from clinical trials and intervention studies assessing meditation-based therapies in schizophrenia. Metrics included changes in symptom severity, cognitive performance, and quality of life using standardized scales such as PANSS and WHO-QOL. Qualitative data were collected through structured interviews with patients and practitioners, analyzed using thematic analysis to identify recurring patterns and insights into the feasibility and cultural acceptance of meditation in schizophrenia care. Statistical analyses were performed to evaluate effect sizes and correlations between meditation practices and symptom improvement. Results: Findings indicate that meditation significantly modulates neural circuits associated with stress and emotional dysregulation, reducing symptom severity and improving coping mechanisms. Quantitative analysis revealed consistent reductions in PANSS scores (p<0.05) and improved quality-of-life measures. Thematic analysis highlighted increased self-awareness and reduced distress from hallucinations as key benefits. Providers emphasized the need for personalized meditation protocols tailored to individual symptom profiles. Conclusion: Meditation offers a promising complementary strategy for managing schizophrenia symptoms, supported by both quantitative and qualitative evidence. Its integration into treatment plans requires interdisciplinary collaboration and sensitivity to cultural contexts. Future research should focus on long-term efficacy and refining protocols to maximize therapeutic outcomes.
- 15 December 2025
- Published by Cifra Ltd – Russian Agency for Digital Standardization (RADS) publishing
- Vol. 1 (1) , 5-15
Open AccessMeditation as a Tool for Symptom Relief in Schizophrenia: Bridging Neuroscience and Mental Health
Background: Schizophrenia, characterized by symptoms such as auditory and visual hallucinations, imposes significant challenges on mental health care. Recent research highlights the potential of meditation to alleviate symptoms by enhancing emotional regulation and neuroplasticity. This study examines the role of meditation as an adjunctive therapy for schizophrenia, exploring its neurobiological underpinnings and practical integration into care models. Methods: A mixed-methods approach was employed. Quantitative data were analyzed from clinical trials and intervention studies assessing meditation-based therapies in schizophrenia. Metrics included changes in symptom severity, cognitive performance, and quality of life using standardized scales such as PANSS and WHO-QOL. Qualitative data were collected through structured interviews with patients and practitioners, analyzed using thematic analysis to identify recurring patterns and insights into the feasibility and cultural acceptance of meditation in schizophrenia care. Statistical analyses were performed to evaluate effect sizes and correlations between meditation practices and symptom improvement. Results: Findings indicate that meditation significantly modulates neural circuits associated with stress and emotional dysregulation, reducing symptom severity and improving coping mechanisms. Quantitative analysis revealed consistent reductions in PANSS scores (p<0.05) and improved quality-of-life measures. Thematic analysis highlighted increased self-awareness and reduced distress from hallucinations as key benefits. Providers emphasized the need for personalized meditation protocols tailored to individual symptom profiles. Conclusion: Meditation offers a promising complementary strategy for managing schizophrenia symptoms, supported by both quantitative and qualitative evidence. Its integration into treatment plans requires interdisciplinary collaboration and sensitivity to cultural contexts. Future research should focus on long-term efficacy and refining protocols to maximize therapeutic outcomes.
- Open Access
- 15 December 2025
- Published by Cifra Ltd – Russian Agency for Digital Standardization (RADS) publishing
- Vol. 1 (1) , 5-15
Meditation as a Tool for Symptom Relief in Schizophrenia: Bridging Neuroscience and Mental Health
Background: Schizophrenia, characterized by symptoms such as auditory and visual hallucinations, imposes significant challenges on mental health care. Recent research highlights the potential of meditation to alleviate symptoms by enhancing emotional regulation and neuroplasticity. This study examines the role of meditation as an adjunctive therapy for schizophrenia, exploring its neurobiological underpinnings and practical integration into care models. Methods: A mixed-methods approach was employed. Quantitative data were analyzed from clinical trials and intervention studies assessing meditation-based therapies in schizophrenia. Metrics included changes in symptom severity, cognitive performance, and quality of life using standardized scales such as PANSS and WHO-QOL. Qualitative data were collected through structured interviews with patients and practitioners, analyzed using thematic analysis to identify recurring patterns and insights into the feasibility and cultural acceptance of meditation in schizophrenia care. Statistical analyses were performed to evaluate effect sizes and correlations between meditation practices and symptom improvement. Results: Findings indicate that meditation significantly modulates neural circuits associated with stress and emotional dysregulation, reducing symptom severity and improving coping mechanisms. Quantitative analysis revealed consistent reductions in PANSS scores (p<0.05) and improved quality-of-life measures. Thematic analysis highlighted increased self-awareness and reduced distress from hallucinations as key benefits. Providers emphasized the need for personalized meditation protocols tailored to individual symptom profiles. Conclusion: Meditation offers a promising complementary strategy for managing schizophrenia symptoms, supported by both quantitative and qualitative evidence. Its integration into treatment plans requires interdisciplinary collaboration and sensitivity to cultural contexts. Future research should focus on long-term efficacy and refining protocols to maximize therapeutic outcomes.
- 15 December 2025
- Published by Cifra Ltd – Russian Agency for Digital Standardization (RADS) publishing
- Vol. 1 (1) , 5-15
Open AccessMeditation as a Tool for Symptom Relief in Schizophrenia: Bridging Neuroscience and Mental Health
Background: Schizophrenia, characterized by symptoms such as auditory and visual hallucinations, imposes significant challenges on mental health care. Recent research highlights the potential of meditation to alleviate symptoms by enhancing emotional regulation and neuroplasticity. This study examines the role of meditation as an adjunctive therapy for schizophrenia, exploring its neurobiological underpinnings and practical integration into care models. Methods: A mixed-methods approach was employed. Quantitative data were analyzed from clinical trials and intervention studies assessing meditation-based therapies in schizophrenia. Metrics included changes in symptom severity, cognitive performance, and quality of life using standardized scales such as PANSS and WHO-QOL. Qualitative data were collected through structured interviews with patients and practitioners, analyzed using thematic analysis to identify recurring patterns and insights into the feasibility and cultural acceptance of meditation in schizophrenia care. Statistical analyses were performed to evaluate effect sizes and correlations between meditation practices and symptom improvement. Results: Findings indicate that meditation significantly modulates neural circuits associated with stress and emotional dysregulation, reducing symptom severity and improving coping mechanisms. Quantitative analysis revealed consistent reductions in PANSS scores (p<0.05) and improved quality-of-life measures. Thematic analysis highlighted increased self-awareness and reduced distress from hallucinations as key benefits. Providers emphasized the need for personalized meditation protocols tailored to individual symptom profiles. Conclusion: Meditation offers a promising complementary strategy for managing schizophrenia symptoms, supported by both quantitative and qualitative evidence. Its integration into treatment plans requires interdisciplinary collaboration and sensitivity to cultural contexts. Future research should focus on long-term efficacy and refining protocols to maximize therapeutic outcomes.